Allergan adopts poison pill against $48bn Valeant bid
This article was originally published in Clinica
Executive Summary
Medical device and pharmaceuticals firm Allergan adopted a stockholder rights plan, otherwise known as a poison pill, late on 22 April to protect its research pipeline and block a bid from Valeant Pharmaceuticals that values Allergan's Botox-led portfolio and late-stage development programs at $48bn.